Bristol-Myers Squibb

CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)

Retrieved on: 
Wednesday, August 4, 2021

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced the publication of three articles in peer-reviewed journals on pacmilimab (CX-072), the Company’s wholly-owned conditionally activated antibody directed against PD-L1 currently being developed in combination with praluzatamab ravtansine (CX-2009) for the treatment of triple-negative breast cancer (TNBC).

Key Points: 
  • Pacmilimab+ipilimumab was administered intravenously every 3 weeks for four cycles, followed by pacmilimab administered every 2 weeks as monotherapy.
  • We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment.
  • First-in-class product candidates against previously undruggable targets include a CD166-targeting conditionally activated antibody-drug conjugate wholly owned by CytomX (praluzatamab ravtansine, CX-2009) and a CD71-targeting conditionally activated antibody-drug conjugate partnered with AbbVie (CX-2029).

Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland

Retrieved on: 
Tuesday, August 3, 2021

Bristol Myers Squibb (NYSE: BMY) today announced that it has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that it has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec.
  • The divestiture is part of Bristol Myers Squibbs ongoing evolution of its manufacturing network to support its product portfolio.
  • Switzerland remains an important strategic location for the Company, and Bristol Myers Squibb expects to maintain a strong presence in the country.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy

Retrieved on: 
Friday, July 30, 2021

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).
  • Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.
  • By harnessing the bodys own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
  • OPDIVO (nivolumab), in combination with cabozantinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients

Retrieved on: 
Friday, July 30, 2021

Vonafexor met the primary endpoint of lowering HBsAg by an average of 1 log10, a key biomarker of viral activity in the liver, after 16 weeks of treatment.

Key Points: 
  • Vonafexor met the primary endpoint of lowering HBsAg by an average of 1 log10, a key biomarker of viral activity in the liver, after 16 weeks of treatment.
  • These results in CHB patients are further positive news for Vonafexor, after the recent disclosure of strong positive clinical results in Non-Alcoholic Steato-Hepatitis (NASH) patients on July 28, 2021.
  • The subjects were thereafter maintained for the next 24 weeks on oral, once-daily 0.5 mg Entecavir only.
  • Established data on CHB patients confirm that more and more patients are HBeAg negative (>80% currently) as a consequence of the chronic evolution of their disease.

All-natural and Organic Ingredients Unlock Lucrative Growth Prospects in Infant Formula Ingredients Space

Retrieved on: 
Thursday, July 29, 2021

SANTA CLARA, Calif., July 29, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global Infant Formula Ingredients Growth Opportunities, finds that the global infant formula ingredients market expands steadily as the demand for high-quality infant formula products that can closely mimic the breast milk composition is on the rise. The market is estimated to hit $8.21 billion by 2025 from $6.37 billion in 2020, an uptick at a compound annual growth rate (CAGR) of 5.2%. Additionally, the growing demand for organic and plant-based infant formulas from health-conscious consumers gives further impetus to the overall industry's growth presenting lucrative growth prospects across the non-allergenic and non- genetically-modified organisms (GMO) plant protein ingredients space.

Key Points: 
  • Additionally, the growing demand for organic and plant-based infant formulas from health-conscious consumers gives further impetus to the overall industry's growth presenting lucrative growth prospects across the non-allergenic and non- genetically-modified organisms (GMO) plant protein ingredients space.
  • "Going forward, across different infant formula segments, volume growth is primarily from the specialty infant formula category, with growing-up/toddler milk estimated to account for a majority of the bulk demand for ingredients, primarily due to its sheer volume.
  • Sharmaadded: "Regulations across the infant formula space are predicted to play a significant role in shaping market dynamics.
  • Moreover, proposed changes in the infant formula national standards (GB standards) in Chinaone of the leading markets of infant formula productsare anticipated to impact the market significantly.

All-natural and Organic Ingredients Unlock Lucrative Growth Prospects in Infant Formula Ingredients Space

Retrieved on: 
Thursday, July 29, 2021

SANTA CLARA, Calif., July 29, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global Infant Formula Ingredients Growth Opportunities, finds that the global infant formula ingredients market expands steadily as the demand for high-quality infant formula products that can closely mimic the breast milk composition is on the rise. The market is estimated to hit $8.21 billion by 2025 from $6.37 billion in 2020, an uptick at a compound annual growth rate (CAGR) of 5.2%. Additionally, the growing demand for organic and plant-based infant formulas from health-conscious consumers gives further impetus to the overall industry's growth presenting lucrative growth prospects across the non-allergenic and non- genetically-modified organisms (GMO) plant protein ingredients space.

Key Points: 
  • Additionally, the growing demand for organic and plant-based infant formulas from health-conscious consumers gives further impetus to the overall industry's growth presenting lucrative growth prospects across the non-allergenic and non- genetically-modified organisms (GMO) plant protein ingredients space.
  • "Going forward, across different infant formula segments, volume growth is primarily from the specialty infant formula category, with growing-up/toddler milk estimated to account for a majority of the bulk demand for ingredients, primarily due to its sheer volume.
  • Sharmaadded: "Regulations across the infant formula space are predicted to play a significant role in shaping market dynamics.
  • Moreover, proposed changes in the infant formula national standards (GB standards) in Chinaone of the leading markets of infant formula productsare anticipated to impact the market significantly.

Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction

Retrieved on: 
Thursday, July 29, 2021

SUZHOU, China, July 28, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to TST001, its anti-Claudin18.2 monoclonal antibody currently in Phase I clinical trial, for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ).

Key Points: 
  • SUZHOU, China, July 28, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to TST001, its anti-Claudin18.2 monoclonal antibody currently in Phase I clinical trial, for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ).
  • According to preclinical and clinical data, TST001 displayed potent anti-tumor activities in tumor model of gastric cancer or patient of gastric cancer expressing Claudin18.2.
  • At present, the treatment options of gastric cancer expressing Claudin18.2 are very limited other than surgical resection, chemotherapy and most recently immunotherapy.
  • Orphan Drug Designation (ODD) is granted by the FDA to drugs intended to treat rare disorders that affect fewer than 200,000 people in the U.S.

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207

Retrieved on: 
Monday, July 19, 2021

We are on track to report preliminary data from the triple combination dose escalation arm of the study in the fourth quarter of this year."

Key Points: 
  • We are on track to report preliminary data from the triple combination dose escalation arm of the study in the fourth quarter of this year."
  • The open-label Phase 1/2 trial is designed to evaluate the safety, tolerability, and preliminary antitumor activity of COM701 in combination with Opdivo and BMS-986207.
  • COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, blocking the interaction with its ligand, PVRL2.
  • Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 single, dual and triple combination studies.

Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck

Retrieved on: 
Friday, July 16, 2021

Squamous cell carcinoma of the head and neck (SCCHN) accounts for more than 90% of all head and neck cancers.

Key Points: 
  • Squamous cell carcinoma of the head and neck (SCCHN) accounts for more than 90% of all head and neck cancers.
  • OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • OPDIVO (nivolumab), in combination with cabozantinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
  • OPDIVO (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

City of Hope and Osel Announce Exclusive License for Intellectual Property on the Use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications

Retrieved on: 
Wednesday, July 14, 2021

The experimental treatment was evaluated in a City of Hope investigator-initiated Phase 1b trial.

Key Points: 
  • The experimental treatment was evaluated in a City of Hope investigator-initiated Phase 1b trial.
  • 4513 titled First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM588 in patients with metastatic renal cell carcinoma is available here .
  • We look forward to working with City of Hope to further investigate how CBM588 can improve the lives of cancer patients.
  • Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy .